Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCRX Pacira Pharmaceuticals

Trading 02-11 14:26:04 EST

21.68

+0.44

+2.07%

High22.02	Low20.88	Vol458.24K
Open21.28	D1 Closing21.24	Amplitude5.37%
Mkt Cap891.05M	Tradable Cap820.46M	Total Shares41.10M
T/O9.88M	T/O Rate1.21%	Tradable Shares37.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":21.68,"timestamp":1770837962034,"preClose":21.24,"halted":0,"volume":458240,"delay":0,"changeRate":0.02071563088512247,"floatShares":37844000,"shares":41100000,"eps":0.471309,"marketStatus":"Trading","change":0.44,"latestTime":"02-11 14:26:04 EST","open":21.28,"high":22.02,"low":20.88,"amount":9883745.56672,"amplitude":0.053672,"askPrice":21.7,"askSize":79,"bidPrice":21.65,"bidSize":184,"shortable":3,"etf":0,"ttmEps":0.471309,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":21.24,"preHourTrading":{"tag":"盘前","latestPrice":21.25,"preClose":21.24,"latestTime":"08:51 EST","volume":8685,"amount":184468.870215,"timestamp":1770817865257,"change":0.01,"changeRate":0.000471,"amplitude":0.037665},"postHourTrading":{"tag":"盘后","latestPrice":21.24,"preClose":21.24,"latestTime":"16:45 EST","volume":12094,"amount":256876.56,"timestamp":1770759914767,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.937543,"impliedVol":0.5097,"impliedVolPercentile":0.4821},"requestUrl":"/m/hq/s/PCRX","defaultTab":"news","newsList":[{"id":"2610536616","title":"BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610536616","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610536616?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:18","pubTimestamp":1770643107,"startTime":"0","endTime":"0","summary":"BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Feb 9 (Reuters) - Pacira Biosciences Inc PCRX.O:PACIRA BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUA6NBXDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2610658450","title":"Pacira Biosciences Grants Inducement Equity Awards to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2610658450","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610658450?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:00","pubTimestamp":1770642023,"startTime":"0","endTime":"0","summary":"Pacira BioSciences, Inc. has granted inducement awards to 14 new employees under its Amended and Restated 2014 Inducement Plan. Four employees received stock options to purchase a total of 58,000 shares of Pacira common stock at an exercise price of $21.02 per share. These options have a 10-year term and vest over four years, with 25 percent vesting after the first year and the remainder vesting in equal quarterly installments over the following three years. Additionally, 14 employees received restricted stock units totaling 41,300 shares, which vest in four equal annual installments starting February 1, 2027. Vesting is contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL1BSqYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","PCRX","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4007","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2608138920","title":"Pacira Biosciences Chief Administrative Officer Kristen Williams Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608138920","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608138920?lang=en_us&edition=fundamental","pubTime":"2026-02-04 07:24","pubTimestamp":1770161077,"startTime":"0","endTime":"0","summary":"Kristen Williams, Chief Administrative Officer of Pacira Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3nJVNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira Biosciences Chief Administrative Officer Kristen Williams Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2607054856","title":"Pacira Biosciences Files Initial Beneficial Ownership Statement for Director Samit Hirawat","url":"https://stock-news.laohu8.com/highlight/detail?id=2607054856","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607054856?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:50","pubTimestamp":1769723441,"startTime":"0","endTime":"0","summary":"Pacira Biosciences Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Samit Hirawat as a director and the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDLb2MV8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Pacira Biosciences Files Initial Beneficial Ownership Statement for Director Samit Hirawat","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2606711109","title":"Pacira appoints Samit Hirawat to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2606711109","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606711109?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:15","pubTimestamp":1769606151,"startTime":"0","endTime":"0","summary":"Pacira BioSciences (PCRX) announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pacira-appoints-samit-hirawat-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pacira-appoints-samit-hirawat-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2606719221","title":"Pacira Biosciences Appoints Samit Hirawat to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719221","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719221?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605216,"startTime":"0","endTime":"0","summary":"Pacira BioSciences, Inc. announced the appointment of Samit Hirawat, M.D., to its Board of Directors, expanding the board to 10 members.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on January 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL2g7j2q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","PCRX","LU2210150020.SGD","SG9999014021.USD","BK4112","BK4007","BK4588"],"gpt_icon":0},{"id":"2606719450","title":"Press Release: Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719450","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719450?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605200,"startTime":"0","endTime":"0","summary":"-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise --. BRISBANE, Calif., Jan. 28, 2026  -- Pacira BioSciences, Inc. , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members.Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL , a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerv","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","PCRX","BK4232","BK4022","BK4007"],"gpt_icon":0},{"id":"2605419190","title":"Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Inspire Medical Systems (INSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605419190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605419190?lang=en_us&edition=fundamental","pubTime":"2026-01-23 02:10","pubTimestamp":1769105435,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX – Research Report), Ins...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-pacira-pharmaceuticals-pcrx-inspire-medical-systems-insp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-pacira-pharmaceuticals-pcrx-inspire-medical-systems-insp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","PCRX","BK4112","BK4585","XBI","BK4167","BK4581","LU2065731478.USD","INSP","BK4137","LU0029874061.USD","BK4007","BK4082","BK4588","LABU"],"gpt_icon":0},{"id":"2603681026","title":"Pacira Biosciences Inc - to Receive Upfront Payment and Royalties From LG Chem","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681026?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8DJFVY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2603045681","title":"Pacira Biosciences Inc - LG Chem Gains Exclusive Rights to Commercialize Exparel","url":"https://stock-news.laohu8.com/highlight/detail?id=2603045681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603045681?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8DJFVY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2603335684","title":"Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2603335684","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603335684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309200,"startTime":"0","endTime":"0","summary":"-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–  BRISBANE, Calif., Jan.  13, 2026  (GLOBE NEWSWIR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217716/0/en/Pacira-Announces-Agreement-with-LG-Chem-to-Make-EXPAREL-Available-in-Select-Asian-Pacific-Markets.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLCT","PCRX","BK4007"],"gpt_icon":0},{"id":"2603540578","title":"Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist Pressure - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540578","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603540578?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:22","pubTimestamp":1768231358,"startTime":"0","endTime":"0","summary":"Pacira BioSciences recently reported preliminary unaudited 2025 revenue of US$726.4 million, modestly above the prior year’s US$701.0 million, while also completing a US$150.05 million buyback totaling 5,932,106 shares since May 2025.\nAt the same time, the company lowered its 2025 revenue forecast and faced fresh pressure from activist DOMA Perpetual Capital Management, which is pushing for board changes and a potential sale process.\nNext, we’ll examine how the downward 2025 revenue forecast...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-63-after-cut-2025-outlook-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-63-after-cut-2025-outlook-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2602873065","title":"Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2602873065","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602873065?lang=en_us&edition=fundamental","pubTime":"2026-01-10 18:24","pubTimestamp":1768040649,"startTime":"0","endTime":"0","summary":"What triggered the latest move in Pacira BioSciences?\nPacira BioSciences (PCRX) has drawn attention after reporting record EXPAREL sales with 7% volume growth in what it called its strongest fourth quarter in three years, along with a completed fourth quarter share repurchase and fresh activist pressure on the board.\nSee our latest analysis for Pacira BioSciences.\nDespite record EXPAREL sales and a completed buyback that retired 13.28% of shares under the May 2025 program, Pacira BioSciences’...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/assessing-pacira-biosciences-pcrx-valuation-after-record-exp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/assessing-pacira-biosciences-pcrx-valuation-after-record-exp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1103631880","title":"Stock Track | Pacira Pharmaceuticals Plummets 13.37% Intraday After Reporting Preliminary FY25 Revenue Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1103631880","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103631880?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:24","pubTimestamp":1767979457,"startTime":"0","endTime":"0","summary":"Pacira Pharmaceuticals (PCRX) saw its stock price plummet by 13.37% during intraday trading on Friday, as investors reacted to the company's preliminary FY25 revenue results.The sharp decline...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PCRX"],"gpt_icon":0},{"id":"2602087053","title":"Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January","url":"https://stock-news.laohu8.com/highlight/detail?id=2602087053","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602087053?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:21","pubTimestamp":1767979285,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/01/49818860/crude-oil-rises-sharply-us-consumer-sentiment-edges-higher-in-january","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TQQQ","BK4087","TSYW.SI","PCRX","USJW.SI","NVIW.SI",".IXIC","BK4121","QID","MNQmain","PSQ","BBNX","CGON","ANPA","NQmain","BK4007","QTRX","QLD","USAW.SI","AQST","SQQQ","BK4139"],"gpt_icon":1},{"id":"2602097373","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Pacira Pharmaceuticals (PCRX) and Beta Bionics, Inc. (BBNX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602097373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602097373?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961839,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME – Research Report), Pacira Pharmaceu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-pacira-pharmaceuticals-pcrx-and-beta-bionics-inc-bbnx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-pacira-pharmaceuticals-pcrx-and-beta-bionics-inc-bbnx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4082","BK4139","LABU","XLV","BK4588","LU0029874061.USD","HCSG","LU0128526141.USD","BK4581","BBNX","XBI","BK4585","BK4007","ZYME","PCRX"],"gpt_icon":0},{"id":"2602321039","title":"Pacira BioSciences Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602321039?lang=en_us&edition=fundamental","pubTime":"2026-01-09 18:01","pubTimestamp":1767952860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 05:01 ET (10:01 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2602319983","title":"Stocks to Watch: Cemtrex, Olin, Pacira BioSciences, Tilray Brands","url":"https://stock-news.laohu8.com/highlight/detail?id=2602319983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602319983?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:32","pubTimestamp":1767915120,"startTime":"0","endTime":"0","summary":"Cemtrex completed its acquisition of a Texas military engineering firm. Shares gained 35.5% to $3.94 in after-hours trading Thursday.Olin cut its fourth-quarter outlook, citing a slowdown in operations at its Freeport, Texas, facility and a decline in chlorine demand. The stock fell 7.8% to $20.80 after the bell.Pacira BioSciences' preliminary revenue results for the year were lower than analysts were expecting. Shares declined 9.7% to $23.50.Tilray Brands said a potential rescheduling of marijuana in the U.S. could boost its medical cannabis business. Shares advanced 7.8% to $9.85.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OLN","TLRY","BK4157","BK4145","CETX","LU1169590202.USD","BK4007","LU1169589451.USD","BK4547","PCRX","BK4090","BK4596","BK4557"],"gpt_icon":0},{"id":"2602531672","title":"Pacira BioSciences Falls After Preliminary Sales Miss Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2602531672","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602531672?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:10","pubTimestamp":1767913800,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates.The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months.The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet.Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected.Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said.For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million.Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira BioSciences Falls After Preliminary Sales Miss Estimates","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2602189243","title":"Pacira 2025 preliminary revenue slightly misses expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2602189243","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602189243?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:12","pubTimestamp":1767906723,"startTime":"0","endTime":"0","summary":"Pacira 2025 preliminary revenue slightly misses expectationsOverviewNon-opioid pain therapy firm's preliminary 2025 revenue slightly missed analyst expectationsEXPAREL sales volume grew 7% in Q4, mark","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL1N3Y912H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU0203347892.USD","BK4567","PCRX","BK4149","BK4588","LU0154245756.USD","LU0154245673.USD","CMI","BK4585","BK4533","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0973},{"period":"3month","weight":-0.1098},{"period":"6month","weight":-0.1501},{"period":"1year","weight":-0.1862},{"period":"ytd","weight":-0.1793}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.04958},{"month":2,"riseRate":0.666667,"avgChangeRate":0.022362},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.005065},{"month":4,"riseRate":0.6,"avgChangeRate":0.040098},{"month":5,"riseRate":0.533333,"avgChangeRate":0.021597},{"month":6,"riseRate":0.4,"avgChangeRate":0.013306},{"month":7,"riseRate":0.4,"avgChangeRate":-0.031855},{"month":8,"riseRate":0.533333,"avgChangeRate":0.016779},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011519},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02773},{"month":11,"riseRate":0.733333,"avgChangeRate":0.066003},{"month":12,"riseRate":0.6,"avgChangeRate":0.042036}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}